← Back to Search

Diuretic

Guided Diuretic Therapy for High Blood Pressure in Chronic Kidney Disease

N/A

Waitlist Available

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult (>18 years old) outpatient with uncontrolled hypertension; defined as, AMBP ≥ 130/80 mmHg despite treatment

Fluid overload of more than 5% of estimated normal ECFV, as assessed by Bio-impedance spectroscopy (using the Body Composition Monitor, a validated device marketed by Fresenius, Canada)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial is testing whether using a patient's bio-impedance to guide diuretic therapy can help control blood pressure in people with hypertensive CKD.

Who is the study for?

This trial is for adults over 18 with uncontrolled high blood pressure and moderate chronic kidney disease, who have fluid overload. They must not be pregnant or breastfeeding, should be able to give consent, and not have had recent surgery or severe conditions like heart failure or cancer.Check my eligibility

What is being tested?

The study tests a diuretic therapy algorithm designed to manage fluid overload in hypertensive patients with chronic kidney disease by using bio-impedance to assess their fluid status.See study design

What are the potential side effects?

Potential side effects may include dehydration, electrolyte imbalances (like low potassium), increased urination, dizziness, headaches, and possibly allergic reactions to the diuretics used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am an adult with high blood pressure not controlled by medication.

Select...

My body has more than 5% excess fluid compared to what's normal, confirmed by a special body fluid test.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Blood pressure

Fluid status

Secondary outcome measures

Vascular stiffness

Side effects data

From 2019 Phase 2 trial • 130 Patients • NCT03136198

NSTEMI type 2

Acute Kidney Injury

Respiratory failure

Bradycardia

Mural thrombus

Nonsustained ventricular tachycardia

Hypotension

NSTEMI

Iron deficiency anemia

MGUS, new diagnosis

Hyperkalemia

Urinary retention

Proteinuria

Pulmonary embolism

Mitral Regurgitation, severe

Mitral valve disease

100%

80%

60%

40%

20%

Study treatment Arm

Usual Care

LUS-guided Strategy-of-care

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention groupExperimental Treatment1 Intervention

Bio-impedance spectroscopy. Treatment algorithm for diuretic therapy.

Group II: Control groupActive Control1 Intervention

No intervention.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor

886 Previous Clinical Trials

384,826 Total Patients Enrolled

Media Library

High Blood Pressure Research Study Groups: Intervention group, Control group

High Blood Pressure Clinical Trial 2023: Diuretic algorithm Highlights & Side Effects. Trial Name: NCT05378750 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still available enrollment in this clinical investigation?

"The information hosted on clinicaltrials.gov suggests that this particular trial is not currently enrolling patients; it was posted on November 1st 2022 and last edited October 18th 2022. Conversely, 1216 other studies are actively recruiting right now so there may be opportunities to participate in medical research elsewhere."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Fluid Overload Management and Vascular Stiffness in Chronic Kidney Disease Patients With Hypertension

2022. "Fluid Overload Management and Vascular Stiffness in Chronic Kidney Disease Patients With Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05378750.